GLAXOPharmaceuticals
GlaxoSmithKline Pharmaceuticals Ltd — PE Ratio & Valuation Analysis
₹2283.00
-3.43%
Current P/E44.39xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E44.0x1.0% above avg
⚠️
39.7% Premium to Industry
GLAXO P/E 44.39x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹54.76 | ₹2474 | 45.2x |
| 2024 | ₹34.83 | ₹2252 | 64.7x |
| 2023 | ₹36.05 | ₹1898 | 52.7x |
| 2022 | ₹100.04 | ₹1319 | 13.2x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding GlaxoSmithKline Pharmaceuticals Ltd Valuation
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) currently trades at 44.39x earnings. The Pharmaceuticals sector average PE is 31.77x. GLAXO commands a premium, reflecting high growth expectations. Historically, GLAXO has traded at an average PE of 44.0x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
46.87%
Dividend Yield
1.68%
More on GlaxoSmithKline Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.